1-4 of 4
Gijs van de Wetering
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10934–10935.
https://doi.org/10.1182/blood-2022-158028
Published: 2022
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

Anuja Chatterjee, MSc, Gijs Van de Wetering, PhD, Ron Goeree, Anne Marie Desbois, Patricia Manzi, MSc, BPharm, Beenish S Manzoor, PhD, Carolyn Owen, MDFRCPC, Kavita Sail, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-134596
Published: 2020
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019
Journal Articles

Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial

Istvan Majer, Arun Krishna, Gijs van de Wetering, Jesús F. San-Miguel, MD PhD, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 4504.
https://doi.org/10.1182/blood.V126.23.4504.4504
Published: 2015